Fms like tyrosine Kinase 3 (FLT3), also named as CD135, FLK2, is receptor kinase receptor, expressed on the surface of many hematopoietic progenitor cells. Overactivation of FLT3-ITD-AXL due to mutation and overexpression can lead to the development and poor prognosis of Leukemia, the identification of FLT3 as a driver gene has led to the repaid development of anti-AML therapeutics, including Sunitinib, Sorafenib and Quizartinib (AC220).
Ba/F3 cell, a murine interleukin-3 dependent pro-B cell line, is a popular system for exploring both kinases and their inhibitors, because some protein kinases can render the Ba/F3 cells to be depended on the activation of the kinases instead of IL-3 supplement, while their inhibitors can antagonize the kinase-dependent growth effects.